Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Alyssa Kassouf, Rina Welkie, Yazeed Sawalha, Audrey Sigmund, Timothy Voorhees, Yun Choi, Robert Baiocchi, Jordan Lundberg, Tracy Wiczer, Tyler Everhardt, Caitlyn Crawford, Rebecca Evers, Lindsay Rosen, Beth Christian, Kami Maddocks, David Bond

Blood (2025) 146 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2025-4526

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Blood (2025) 146 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2025-1935

Published: 2025

Journal Articles

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Timothy Voorhees, Rina Welkie, Hemalatha Rao, Yazeed Sawalha, David Bond, Audrey Sigmund, Yun Choi, John Reneau, Walter Hanel, Polina Shindiapina, Jonathan Brammer, Beth Christian, Lapo Alinari, Nancy Bartlett, Kami Maddocks, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 8240.

https://doi.org/10.1182/blood-2025-8240

Published: 2025

Journal Articles

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Yazeed Sawalha, Marie Hu, Rina Welkie, Aubree Shoemaker, Yun Choi, Audrey Sigmund, Timothy Voorhees, David Bond, John Reneau, Lapo Alinari, Jonathan Brammer, Beth Christian, Robert Baiocchi, Veronika Bachanova, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8239.

https://doi.org/10.1182/blood-2025-8239

Published: 2025

Journal Articles

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Bruce D. Cheson, Nancy L. Bartlett, Betsy R. LaPlant, Hun Ju Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana Feldman, Stephen M. Ansell

Blood (2024) 144 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2024-207424

Published: 2024

Journal Articles

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Sonia Godbole, Rina Li Welkie, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C. Reneau, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks, Yazeed Sawalha

Blood (2024) 144 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2024-207738

Published: 2024

Journal Articles

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Blood (2024) 144 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2024-202639

Published: 2024

Journal Articles

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2024-203798

Published: 2024

Journal Articles

Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)

John Sharp, Subodh Bhatta, Noah Takacs, Kathleen Tong, Youssef Youssef, David A. Bond, Yazeed Sawalha, Audrey M. Sigmund, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Kami J. Maddocks, Beth Christian, Timothy Voorhees, Narendranath Epperla

Blood (2024) 144 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2024-194399

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Journal Articles

Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Narendranath Epperla, Natalie Grover, Pallawi Torka, Reem Karmali, Kaitlin Annunzio, Marcus P. Watkins, Andrea Carolina Anampa-Guzmán, Heather Reves, Montreh Tavakkoli, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Geoffrey Shouse, Nancy L. Bartlett, Adam J. Olszewski

Blood (2024) 144 (Supplement 1): 398.

https://doi.org/10.1182/blood-2024-202697

Published: 2024

Journal Articles

Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2024-202721

Published: 2024

Journal Articles

Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

David A. Bond, Ying Huang, John C. Reneau, Yazeed Sawalha, Jonathan E. Brammer, Timothy Voorhees, Narendranath Epperla, Audrey M. Sigmund, Lapo Alinari, Walter Hanel, Anna Gilmore, Misty Fleming, Kathleen Stamper, Robert Baiocchi, Beth Christian, Kami J. Maddocks

Blood (2024) 144 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2024-194545

Published: 2024

Journal Articles

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2024-206559

Published: 2024

Journal Articles

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks

Blood (2023) 142 (Supplement 1): 6226.

https://doi.org/10.1182/blood-2023-182941

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Narendranath Epperla, Kaitlin Annunzio, Geoffrey P. Shouse, Natalie S. Grover, Pallawi Torka, Marcus P Watkins, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2023-185182

Published: 2023

Journal Articles

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Narendranath Epperla, Natalie S. Grover, Kaitlin Annunzio, Marcus P Watkins, Pallawi Torka, Reem Karmali, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey P. Shouse, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 266.

https://doi.org/10.1182/blood-2023-185152

Published: 2023

Journal Articles

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Allison M Lehanka, Ann Kebede, Neda Amirmokhtari, Joseph R Stanek, Narendranath Epperla, Beth Christian, Robert Baiocchi, Timothy Voorhees, Kami J. Maddocks, Yazeed Sawalha, John C Reneau, Jonathan E. Brammer, Audrey M. Sigmund, Faye Willen, Nick Yeager, Anthony N. Audino, David A. Bond

Blood (2023) 142 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2023-187194

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study

Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only